|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
110.66(B) |
Last
Volume: |
383,195 |
Avg
Vol: |
759,306 |
52
Week Range: |
$692.45 - $1071.19 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
192,108 |
255,165 |
311,759 |
469,743 |
Total Sell Value |
$188,697,290 |
$247,812,013 |
$294,950,701 |
$405,465,351 |
Total People Sold |
7 |
14 |
16 |
18 |
Total Sell Transactions |
18 |
43 |
67 |
128 |
End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Terifay Robert J |
SVP Commercial |
|
2015-03-16 |
4 |
D |
$444.46 |
$5,947,764 |
D/D |
(13,382) |
31,022 |
|
- |
|
Terifay Robert J |
SVP Commercial |
|
2015-03-16 |
4 |
OE |
$30.63 |
$746,606 |
D/D |
24,375 |
44,404 |
|
- |
|
Larosa Joseph J |
SVP General Counsel and Secret |
|
2015-03-16 |
4 |
OE |
$59.20 |
$1,200,635 |
D/D |
20,281 |
11,970 |
|
- |
|
Larosa Joseph J |
SVP General Counsel and Secret |
|
2015-03-16 |
4 |
AS |
$450.00 |
$8,239,950 |
D/D |
(18,311) |
10,000 |
|
- |
|
Mccorkle Douglas S |
VP Controller and Asst Treasur |
|
2015-02-27 |
4 |
S |
$416.24 |
$1,248,720 |
D/D |
(3,000) |
4,481 |
|
- |
|
Tessier-Lavigne Marc |
Director |
|
2015-02-26 |
4 |
S |
$420.33 |
$1,265,864 |
D/D |
(3,000) |
1,187 |
|
- |
|
Tessier-Lavigne Marc |
Director |
|
2015-02-26 |
4 |
OE |
$50.91 |
$152,730 |
D/D |
3,000 |
4,187 |
|
- |
|
Terifay Robert J |
SVP Commercial |
|
2015-02-24 |
4 |
AS |
$423.67 |
$4,733,665 |
D/D |
(11,173) |
20,029 |
|
- |
|
Aberman Michael S |
SVP Strategy Investor Relation |
|
2015-02-24 |
4 |
AS |
$416.31 |
$1,411,952 |
D/D |
(3,374) |
18,600 |
|
- |
|
Terifay Robert J |
SVP Commercial |
|
2015-02-23 |
4 |
D |
$427.94 |
$5,649,664 |
D/D |
(13,202) |
31,202 |
|
- |
|
Terifay Robert J |
SVP Commercial |
|
2015-02-23 |
4 |
OE |
$30.63 |
$746,606 |
D/D |
24,375 |
44,404 |
|
- |
|
Aberman Michael S |
SVP Strategy Investor Relation |
|
2015-02-23 |
4 |
D |
$427.94 |
$1,765,680 |
D/D |
(4,126) |
21,974 |
|
- |
|
Aberman Michael S |
SVP Strategy Investor Relation |
|
2015-02-23 |
4 |
OE |
$30.63 |
$229,725 |
D/D |
7,500 |
26,100 |
|
- |
|
Van Plew Daniel P |
SVP & General Mgr Industrial O |
|
2015-02-23 |
4 |
S |
$426.08 |
$4,034,754 |
D/D |
(9,431) |
18,705 |
|
- |
|
Sing George L |
Director |
|
2015-02-20 |
4 |
S |
$423.12 |
$6,346,800 |
D/D |
(15,000) |
112,772 |
|
- |
|
Sing George L |
Director |
|
2015-02-20 |
4 |
OE |
$18.61 |
$279,150 |
D/D |
15,000 |
127,772 |
|
- |
|
Van Plew Daniel P |
SVP & General Mgr Industrial O |
|
2015-02-20 |
4 |
D |
$424.70 |
$4,488,654 |
D/D |
(10,569) |
28,136 |
|
- |
|
Van Plew Daniel P |
SVP & General Mgr Industrial O |
|
2015-02-20 |
4 |
OE |
$21.25 |
$425,000 |
D/D |
20,000 |
38,705 |
|
- |
|
Ryan Arthur F |
Director |
|
2015-02-20 |
4 |
S |
$421.72 |
$12,372,908 |
D/D |
(29,250) |
47,500 |
|
- |
|
Ryan Arthur F |
Director |
|
2015-02-20 |
4 |
OE |
$33.42 |
$3,679,498 |
D/D |
29,250 |
76,750 |
|
- |
|
Brown Michael S |
Director |
|
2015-02-20 |
4 |
S |
$422.72 |
$422,720 |
D/D |
(1,000) |
0 |
|
- |
|
Brown Michael S |
Director |
|
2015-02-20 |
4 |
OE |
$57.11 |
$57,110 |
D/D |
1,000 |
1,000 |
|
- |
|
Goldstein Joseph L |
Director |
|
2015-02-20 |
4 |
S |
$423.61 |
$2,118,262 |
D/D |
(5,000) |
4,000 |
|
- |
|
Goldstein Joseph L |
Director |
|
2015-02-20 |
4 |
OE |
$177.82 |
$889,100 |
D/D |
5,000 |
9,000 |
|
- |
|
Aberman Michael S |
SVP Strategy Investor Relation |
|
2015-02-17 |
4 |
AS |
$401.54 |
$1,493,266 |
D/D |
(3,692) |
18,600 |
|
- |
|
2430 Records found
|
|
Page 51 of 98 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|